December 29, 2011 — Medrad Inc. recently released the Certegra Informatics Connect.RIS vendor-neutral informatics application. The system establishes connectivity between Medrad's Stellant contrast-injection systems, and hospital radiology reporting systems and radiology information systems (RIS).  

The Connect.RIS application auto-populates contrast-injection records into radiology reporting systems and RIS, eliminating the need for radiologists to look-up or dictate contrast-injection records. In addition, the application delivers consistent patient records throughout facilities, and supports accurate and efficient billing and reconciliation processes.

Connect.RIS is part of the Certegra informatics platform, Medrad’s Contrast Dose Management solution. Certegra is comprised of a comprehensive line of products designed to support radiology professionals' clinical and administrative needs. The applications automatically document and integrate computed tomography (CT) contrast-injection records across clinical systems – using the injector as the source. Injector-based P3T software individualizes contrast protocols at the point-of-care. Certegra products work in any combination with Medrad's Stellant contrast-injection systems.

Additional Certegra software and applications include:

  • Manage.Report Application (data-driven reporting and analysis across CT suites and shifts):
    • Continually measures and helps radiology professionals actively manage performance department-wide
    • Helps to identify and uncover root cause of atypical events, re-scans and more
  • Connect.PACS application (PACS integration):
    • Automatically captures and integrates CT contrast-injection records (including the protocols programmed and delivered) into picture archiving and communications systems (PACS)
    • Provides radiologists new information concerning the contrast-injections associated with clinical images as they read
    • Allows radiologists to relate their evaluation of clinical images to any changes made at the point-of-care to the protocol prescribed
  • P3T software line (personalized CT contrast protocols for abdomen, cardiac and pulmonary angiography studies):
    • Enables consistent protocol optimization across patient populations and simplifies complex study administration
    • Enables a higher percentage of diagnostic studies and reduces the potential for unnecessary rescans

For more information: www.medrad.com


Related Content

News | X-Ray

April 29, 2026 — Results from a new study* presented at the American Roentgen Ray Society’s (ARRS) 2026 annual meeting ...

Time April 29, 2026
arrow
News | Imaging Software Development

April 28, 2026 — Avatar Medical has been granted FDA 510(k) clearance for Avatar Medical Vision, its software platform ...

Time April 28, 2026
arrow
News | Cardiac Imaging

April 28, 2026 — Abbott has received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its next ...

Time April 28, 2026
arrow
News | Artificial Intelligence

April 20, 2026 — DeepTek, provider of the Augmento platform and deepc, the company behind deepcOS, have introduced a ...

Time April 23, 2026
arrow
News | FDA

April 16, 2026 — Royal Philips has received U.S. Food and Drug Administration 510(k) clearance for the Philips Spectral ...

Time April 20, 2026
arrow
News | Radiology Imaging

April 7, 2026 — Onvida Health and Siemens Healthineers have entered a 10-year Value Partnership¹ designed to bring the ...

Time April 09, 2026
arrow
News | Radiology Business

March 31, 2026 — Radon Medical Imaging, a medical imaging equipment maintenance and repair services company, has has ...

Time March 31, 2026
arrow
News | Radiology Imaging

March 26, 2026 — GE HealthCare has announced a renewed research collaboration with Stanford Medicine Department of ...

Time March 30, 2026
arrow
News | Cardiac Imaging

March 28, 2026 — When Ashley Perlow felt a sharp pain shoot across her chest and into both wrists, she didn't think it ...

Time March 30, 2026
arrow
News | FDA

March 24, 2026 — MARS Bioimaging, a New Zealand–headquartered medical device company, has received U.S. Food and Drug ...

Time March 25, 2026
arrow
Subscribe Now